Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries.

T A McCaffrey, …, K I Kivirikko, D J Falcone


Restenosis occurs in 35% of patients within months after balloon angioplasty, due to a fibroproliferative response to vascular injury. These studies describe a combined fibrosuppressive/antiproliferative strategy on smooth muscle cells cultured from human primary atherosclerotic and restenotic coronary arteries and from normal rat aortas. L-Mimosine suppressed the posttranslational hydroxylation of the precursors for collagen and for eukaryotic initiation factor-5A (eIF-5A) by directly inhibiting the specific protein hydroxylases involved, prolyl 4-hydroxylase (E.C. 1.14.11.2) and deoxyhypusyl hydroxylase (E.C. 1.14.99.29), respectively. Inhibition of deoxyhypusyl hydroxylation correlated with a dose-dependent inhibition of DNA synthesis. Inhibition of prolyl hydroxylation caused a dose-dependent reduction in the secretion of hydroxyproline-containing protein and decreased the formation of procollagen types I and III. The antifibroproliferative action could not be attributed to nonspecific or toxic effects of mimosine, appeared to be selective for the hydroxylation step in the biosynthesis of the procollagens and of eIF-5A, and was reversible upon removal of the compound. The strategy of targeting these two protein hydroxylases has important implications for the pathophysiology of restenosis and for the development of agents to control fibroproliferative diseases.

Find the latest version:

http://jci.me/117684-pdf
Specific Inhibition of eIF-5A and Collagen Hydroxylation by a Single Agent
Antiproliferative and Fibrosuppressive Effects on Smooth Muscle Cells from Human Coronary Arteries

Timothy A. McCaffrey,* Kenneth B. Pomerantz,* Timothy A. Sanborn, Artur M. Spokojny, Baoheng Du,* Myung-Hee Park, John E. Folk, Arja Lamberg, Kari I. Kivilikko, Domenick J. Falcone, Semil B. Mehta,* and Hartmut M. Hanauske-Abel†

*Department of Medicine, Division of Hematology/Oncology, †Department of Pathology, Cell Biology and Anatomy, ‡Cardiac Catheterization Laboratory, and §Department of Pediatrics, Cornell University Medical College, The New York Hospital, New York 10021; §National Institutes of Health, National Institute of Dental Research, Laboratory of Cellular Development and Oncology, Bethesda, Maryland 20892; and **Department of Medical Biochemistry, Oulu University, Oulu, Finland

Abstract

Restenosis occurs in 35% of patients within months after balloon angioplasty, due to a fibroproliferative response to vascular injury. These studies describe a combined fibrosuppressive/antiproliferative strategy on smooth muscle cells cultured from human primary atherosclerotic and restenotic coronary arteries and from normal rat aortas. L-Mimosine suppressed the posttranslational hydroxylation of the precursors for collagen and for eukaryotic initiation factor-5A (eIF-5A) by directly inhibiting the specific protein hydroxylases involved, prolyl 4-hydroxylase (E.C. 1.14.11.2) and deoxypseudyl hydroxylase (E.C. 1.14.99.29), respectively. Inhibition of deoxypseudyl hydroxylation correlated with a dose-dependent inhibition of DNA synthesis. Inhibition of prolyl hydroxylation caused a dose-dependent reduction in the secretion of hydroxyproline-containing protein and decreased the formation of procollagen types I and III. The antifibroproliferative action could not be attributed to nonspecific or toxic effects of mimosine, appeared to be selective for the hydroxylation step in the biosynthesis of the procollagens and of eIF-5A, and was reversible upon removal of the compound. The strategy of targeting these two protein hydroxylases has important implications for the pathophysiology of restenosis and for the development of agents to control fibroproliferative diseases. (J. Clin. Invest. 1995; 95:446–455.) Key words: vascular smooth muscle • cell division • collagen • hydroxylases • mimosine

Introduction

Cell proliferation and matrix production are important elements of any tissue’s response to injury. Both processes are essential in physiological wound repair, but, in excess, they contribute to pathological conditions that can compromise organ function. One of the most destructive clinical manifestations of excessive wound healing occurs at focal sites in the vasculature. Atherosclerotic lesions, with their associated mineralization and lipid accumulation, lead to ischemic, rheological, and prothrombotic complications in coronary, carotid, and peripheral arteries (1). Although angioplasty can achieve initial repulsion in 95% of atherosclerotic occlusions, progressive fibroproliferative reclosure occurs within 6 mo postoperatively in at least 35% of the more than 300,000 patients in the United States alone (2). Despite promising results in animal models, restenosis in humans has been resistant to a variety of medical interventions (for review see reference 2).

The predominant proliferative component of the restenotic lesion is a large dendritic cell expressing the contractile α-actin isoform (3), a marker for both smooth muscle cells (SMC) and myofibroblasts (4). SMC derived from restenotic lesions proliferate more rapidly than cells from primary atherosclerotic lesions (5, 6). In experimental models of arterial injury, SMC show a proliferative peak 4–7 d after injury followed by elevated proliferation for weeks after injury (7, 8). SMC at the injury site rapidly increase gene expression of profibrotic cytokines such as transforming growth factor-β1 (TGF-β1), followed by markedly enhanced expression of collagen type I and III component α chains (9). SMC derived from restenotic lesions produce two- to threefold higher levels of collagen and proteoglycans than SMC derived from umbilical arteries (10). Collagens are known to act as a scaffold for proteoglycans and glycoproteins (11, 12) and, thus, form a depository for TGF-β1 (13–15), PDGF (16), and the fibroblast growth factors (17). These matrix-bound mediators could provide an ongoing signal for proliferation, matrix production, and augmented growth factor expression (18). In this way, the de novo synthesis of collagens could create an intraleisional nidus of profibrotic growth factors which sustain the fibroproliferative response.

We noted that both cell proliferation and extracellular matrix formation depend on the hydroxylation of specific proteins, the eukaryotic initiation factor-5A (eIF-5A) and the collagens, respectively. In eIF-5A, this unique hydroxylated amino acid residue is hypusine [N°-(4-amino-2(R)-hydroxybutyl)lysine]. The synthesis of functional eIF-5A involves two distinct posttranslational modifications: (α) the NAD⁺-dependent transfer of a spermidine-derived 4-aminobutyl moiety onto the ε-amino...
group of a single sequence-defined lysine residue, generating deoxyhypusine (19); and (b) the stereospecific hydroxylation of its carbon 9 by the metalloenzyme deoxyhypusyl hydroxylase (E.C. 1.14.99.29), generating hypusine (20). Hypusine has been identified only in eIF-5A (21, 22). Inhibition of deoxyhypusyl hydroxylase correlates with reversible arrest of cell proliferation, causing the accumulation of cells in the late G1 phase of the cell cycle, apparently by interfering with the onset of DNA replication (21, 23).

In collagens, the crucial hydroxylated residues are trans 4-hydroxyprolines, formed posttranslationally by prolyl 4-hydroxylase (E.C. 1.14.11.12). This enzyme, an α2β2-tetrameric, dimeric iron-containing dioxygenase, stoichiometrically uses 2-oxoglutarate and molecular oxygen for the hydroxylation of a sequence-defined proline residue. The mechanism of prolyl 4-hydroxylase proposed by Hanauske-Abel and Günzler (24) has been used successfully to guide the design of prolyl 4-hydroxylase inhibitors (25, 26). Suppression of prolyl hydroxylase prevents the formation of the collagenous triple helix which is required for the secretion of at least the interstitial procollagens. In this way, inhibition of prolyl 4-hydroxylase selectively reduces formation of the extracellular matrix (25).

The active sites of deoxyhypusyl hydroxylase and prolyl 4-hydroxylase have been probed with reporter molecules (27, 28). Both protein hydroxylases recognize -Gly-x-y-Gly- motifs in their respective substrates and both of their active sites contain (a) a tightly bound metal ion accessible to low molecular weight ligands; and (b) an ionic side chain for salt-bridging ligands. Certain catecholpeptides which mimic the -Gly-x-y-Gly- motif and inhibit purified prolyl 4-hydroxylase also suppress deoxyhypusyl hydroxylase in vitro (27). Nonpeptide compounds like 3,4-dihydroxybenzoic acid (3,4-DHBA) also inhibit both protein hydroxylases (27, 29). The catecholpeptides and 3,4-DHBA are, however, not stable under physiological conditions due to the redox reactivity of their aromatic dihydroxybenzene moiety (30). Thus, l-mimosine, a naturally occurring catechol analogue with a biologically stable, nonaromatic 3-hydroxypryridin-4-one ring, was selected as a pilot compound (Fig. 1).

These studies provide the first evidence that mimosine, but not its ring isomer kojic acid, acts as an inhibitor for both protein hydroxylases in cultured vascular cells. The suppression of cell proliferation and collagen secretion is demonstrated in rat aortic SMC and in cells from primary stenosing and restenotic human coronary lesions. Local delivery of this type of protein hydroxylase inhibitor during recanalization procedures might favorably influence the fibroproliferative sequelae of vascular interventions.

**Methods**

Reagents. l-Mimosine (3-(N-(3-hydroxypryridin-4-one))-2[S]-amino-propionic acid) and kojic acid (5-hydroxy-2-hydroxymethyl-γ-pyrone) were purchased from Aldrich Chemical Co. (Milwaukee, WI). The radiochemicals [terminal methylene-3H](N)-l-spermidine (15 Ci/mmole), [5-3H]-proline (28 Ci/mmole), 2-oxo-[1-14C]glutarate (40 mCi/mmole), and [methyl-3H]thymidine (20 Ci/mmole) were purchased from New England Nuclear (Wilmington, DE). (Pro-Pro-Gly)0 × 9 H2O was obtained from the Protein Research Foundation (Minoh, Osaka, Japan). Catalase was obtained from Sigma Chemical Co. (St. Louis, MO).

**Human tissue sampling.** Coronary vessel wall biopsies were obtained by directional atherectomy (Simpson AtheroCath; DVI, Inc., Redwood City, CA) as a part of routine procedures from patients undergoing interventional treatment for coronary stenosis in the Coronary Catherization Unit of The New York Hospital/Cornell Medical Center, New York. All specimens used in this study were waste tissue collected in accordance with a protocol approved by the Institutional Review Board.

**Cell culture.** Human coronary SMC were obtained by the following procedure. Atherectomy specimens were finely diced and placed onto collagen-coated (Vitrogen; Collagen Corp., Palo Alto, CA) flasks in medium 199 containing 20% fetal bovine serum (FBS) and gentamycin sulfate (50 μg/ml, all from Gibco Laboratories, Grand Island, NY). Cells extending from the explants onto the flask surfaces were subpassed with trypsin/EDTA (Gibco Laboratories) and used within the first five passages. Cell cultures were obtained from primary atherosclerotic and from restenotic lesions as specified for each experiment. Rat aortic SMC were isolated similarly from explants of the aortic media of male Sprague-Dawley rats and cultured in medium 199/10% FBS/gentamicin sulfate.

**Histology.** A portion of each atherectomy specimen was fixed in 10% buffered formalin for routine histology. Both formalin-fixed tissue and cells plated onto 8-chamber glass slides were immunostained using a mouse monoclonal antibody specific for the contractile smooth muscle α-actin (clone No. 1A4; Sigma Chemical Co.) which was detected with FITC- or peroxidase-labeled anti–mouse immunoglobulins (Sigma Chemical Co.). Nonimmune mouse serum was used as a control and showed no staining. Sections were photographed with a Nikon Labophot 2 fluorescence microscope.

**Cell proliferation.** Inhibition of DNA synthesis was examined by semiautomated methods. SMC were plated at 1 × 104 cells/well of 96-well microtiter plates at least 24 h before the assay. Agents were introduced into normal serum-containing growth media for 20 h before the cells were pulse labeled with [3H]thymidine (1 μCi/ml) for 4 h. Cells were collected with trypsin and a cell harvester (Wallac, Gaithersburg, MD), and the DNA-incorporated label was determined by scintillation counting (Betaplate; Wallac) (n = 6 per point).

**Toxicity.** The effect of mimosine and kojic acid on cellular integrity and metabolic function was determined by standard techniques. The release of lactate dehydrogenase (LDH) was determined in serum-free SMC supernatants using an autoanalyzer (Synchron CX7; Beckman Instruments, Inc., Fullerton, CA). Membrane integrity was verified by trypan blue exclusion.

**Deoxyhypusyl hydroxylation in cells.** To determine the conversion of deoxyhypusine to hypusine in cells, nonconfluent cultures of human or rat SMC (1 × 104 cells per 25-cm2 flask) were preincubated for 60 min at the specified inhibitor concentrations. Cells were then labeled with [1H]spermidine (5 μCi/ml) for 24 h, harvested with trypsin/EDTA, and precipitated three times with 10% TCA containing 1 mM each of putrescine, spermidine, and spermine. The final precipitate was hydrolyzed (6 N HCl, 110°C, 16 h), lyophilized, resuspended in water, and analyzed on an amino acid analyzer as described (31).

**Prolyl hydroxylation in cells.** Human or rat SMC (3–5 × 104 cells/...
was bated in type baculovirus transfer

I enzyme was purified tetrameric Wilmington, was 21-amino

on a cellular 2 hydroxylatable substrate, 60

dm at

Spodoptera frugiperda (33, 34), using an automated HPLC system (Hewlett-Packard Co., Wilmington, DE) with an in-line scintillation counter (Inus Systems, Inc., Tampa, FL). All concentrations were tested in replicates of three wells.

Assays of purified human prolyl 4-hydroxylase. The native αβ2-
tetrameric enzyme was purified to homogeneity by poly(L-proline) affinity chromatography and DEAE chromatography from the supernatant of Spodoptera frugiperda insect cells cotransfected with recombinant baculovirus transfer vectors for both the human α- and β-subunits (35).

Enzyme activity was determined by trapping of 4CO2 released from 2-

oxo[1-14C]glutarate as described (28). Briefly, all incubations were run for 60 min at 37°C in a final volume of 1.0 ml per test sample, containing 0.1 μg enzyme, 0.1 mg heat-denatured (Pro-Pro-Gly)10 × H2O as hydroxylatable substrate, 0.1 mM 2-oxo[1-14C]glutarate adjusted to 60,000 dpm by mixing with the unlabeled 2-oxoglutarate as cosubstrate, and cofactors (1.6 mM ascorbate, 0.05 mM ferrous sulfate, 0.08 mM dithiothreitol, 2 mg BSA, 3.750 U catalase).

Determination of type I and type III procollagen secretion. Human SMC (3–5 × 104 cells/35-mm well), grown to confluence and incubated in serum-free DME containing 50 μg/ml sodium ascorbate and 20 μg/ml β-aminopropionitrile, were exposed to 24 h to increase concentrations of test compounds. After centrifugation, to clear any cellular debris, these supernatants were used to determine the levels of type I and III procollagens.

For determination of type I procollagen, supernatants were precipitated with 10% TCA and electrophoresed under nonreducing conditions on a 4–20% SDS-PAGE gel. The gel was transferred to nitrocellulose with a semidy blotter (Bio-Rad Laboratories, Hercules, CA). The membrane was blocked with 1% goat serum/1% BSA and then incubated with a 1:200 dilution of a rabbit polyclonal antiserum (LF41) against a 21-amino acid synthetic peptide homologous to the COOH-terminal sequence of the C-propeptide of the component α1 chain of human type I procollagen. Because in each type I procollagen molecule two of these globular domains are disulfide-linked to the COOH-terminal globular domain of one component α2 chain, this antibody can be used under nonreducing conditions to detect trimeric, native C-propeptide [C3] proteolytically released during procollagen-collagen conversion (36).

The antisera was raised by Dr. L. Fisher (National Institutes of Health, Bethesda, MD) and kindly provided by Dr. D. J. Prockop (Jefferson University, Philadelphia, PA). Nonimmune rabbit serum was used as a control and did not detect bands in the C3 region. Immunoblots were scanned with a UMAX UC630 flatbed scanner and quantified densitometrically using NIH Image software for the Macintosh.

For determination of type III procollagen, supernatants were analyzed by RIA (PIIINP RIA-gnost™; Behringwerke-Hoechst AG, Frankfurt, Germany) for antigenic material derived from the NH2-terminal propeptide of type III procollagen (PIIINP). This assay uses a monoclonal mouse antibody (MAK 226) that preferentially recognizes intact human PIIINP and has low affinity for PIIINP degradation products such as the Col-1 fragment (RIA-gnost P III P technical manual, p. 12). The antigen concentration in each sample was interpolated from a PIINP standard curve. Sample wells were assayed in duplicate and a minimum of three wells per concentration were averaged. The Plasminogen activator inhibitor-1 (PAI-1) assay. Supernatants of human atherectomy-derived SMC incubated with mimosine or kojic acid under serum-free conditions (to avoid plasma-derived inhibitors) were tested for their ability to inhibit a standard amount of urokinase-type plasminogen activator in the presence of plasminogen and the fluorometric peptide plasin substrate d-Val-Leu-Lys-aminomethylcou- marin (Enzyme Systems, Livermore, CA). Inhibition of plasmin genera-
tion was compared with a standard curve of human PAI-1 (American Diagnostica Inc., Greenwich, CT) to yield PAI-1 activity.

Results

Subculture of human vascular cells. Morphologically, coronary artery wall biopsies were notable for their relative acellularity, and the abundant accumulation of collagen, as visualized by the prominent blue counterstaining with Masson’s trichrome technique (37) (Fig. 2, upper left). Both primary atherosclerotic and restenotic lesions showed strong immunostaining for the contractile smooth muscle α-actin isoform in the majority of the large, noninflammatory cells, consistent with the presence of SMC (3, 38) or related myofibroblasts (4) (Fig. 2, upper right).

Atherectomy specimens from 195 patients undergoing treatment for coronary stenosis or restenosis were examined for their ability to yield primary cultures. In 21% of the specimens, cells initially spread onto the culture flask surface, but only 4% produced sustained cultures of SMC. Cells proliferating from these explants can show delayed outgrowth (average latency is 24 d), long doubling times, and abrupt growth inhibition upon minimal cell–cell contact. These cells exhibited long dendritic projections (Fig. 2, lower left). A high percentage (30–40%) of cells spontaneously showed strong reactivity toward the anti–α-actin antibody (Fig. 2, lower right), and essentially all cells became α-actin–positive upon serum withdrawal and treatment with TGF-β1 (< 1 ng/ml), a characteristic of both SMC (39) and myofibroblasts (4, 40).

Effect of mimosine and kojic acid on cellular deoxyhypusyl hydroxylase activity. The inhibition of deoxyhypusyl hydroxy-
lase has been shown to correlate with proliferative arrest at the GI-S boundary (23). When the enzyme was studied in vitro, mimosine caused almost complete inhibition at 50 μM, whereas even 300 μM of kojic acid was not inhibitory (23). Deoxyhypusyl hydroxylase activity in SMC was also not suppressed by kojic acid (data not shown), but mimosine had a marked inhibitory effect. In atherectomy-derived human SMC and in normal rat aortic SMC, mimosine caused a dose-dependent decrease of the enzyme’s hydroxylated product, hypusine, and a concomitant increase in the unhydroxylated intermediate, deoxyhypusine (Fig. 3). Metabolic labeling of the SMC with [3H]- spermidine for 24 h, followed by acid hydrolysis and amino acid analysis, revealed that, under control conditions, especially all of the [3H]spermidine-derived radioactivity was found in a single peak eluting in the position of purified hypusine. At 400 μM mimosine, however, most of the [3H]spermidine-derived, protein-bound label in the human cells was shifted into the position of deoxyhypusine. Significantly, despite this marked suppression of cellular deoxyhypusyl hydroxylase activity (80%), mimosine had only a marginal effect (15%) on the overall incorporation of [3H]spermidine-derived label into precursor eIF-5A (Fig. 3, inset). Dose–response analysis in rat SMC confirmed that maximal inhibition of cellular deoxyhypusyl hydroxylase activity is achieved at 400 μM mimosine, with an apparent half-maximal inhibitory concentration (IC50) of 160 μM (Fig. 3). Total [3H]spermidine incorporation was unaffected in the 100–200 μM range and was reduced at 400 μM by just 11%. These findings suggest that significant disruption by mimosine of the metabolic steps before hydroxylation of the eIF-5A precursor did not occur. Apparently, the biosynthetic flow through the hypusination pathway, with its key elements
Figure 2. Histology, immunocytochemistry, and cell culture of human coronary atherosclerotic lesions recovered by directional atherectomy. Upper left, Masson's trichrome stain of a restenotic lesion recovered from a 60-yr-old male 4.5 mo after balloon angioplasty showing the presence of a few large dendritic cells (red) within an extensive collagenous matrix (blue). Upper right, Immunocytochemical identification (immunoperoxidase) of contractile α-actin-reactive cells showing the presence of smooth muscle-like cells (reddish brown) within the atherosclerotic lesion (Bar = 20 μm for both upper panels). Lower left, Phase-contrast micrograph of cells cultured from explants of the lesion shown in the upper right (Bar = 20 μm for both lower panels). Lower right, Immunocytochemical identification (FITC) of α-actin contractile fibers within one of the cells shown in the previous panel.

The effect of mimosine and kojic acid on vascular cell proliferation. Mimosine was a potent inhibitor of DNA synthesis in SMC derived from primary atherosclerotic lesions, with an apparent IC₅₀ of ~ 90 μM (Fig. 4, top). Two separate SMC cultures derived from restenotic lesions were also inhibited by mimosine by an average of 90% at 500 μM, with an average IC₅₀ of 100 μM (not shown). In contrast, kojic acid was not an effective antiproliferative agent in the dose range tested. Likewise, DNA replication in primary cultures of rat aortic SMC was inhibited by mimosine with an apparent IC₅₀ of 100 μM (Fig. 4, bottom). In cells from both species, inhibition of proliferation was essentially complete at 400 μM mimosine,
whereas kojic acid had little effect up to 1 mM. Mimosine's antiproliferative effect extended with similar dose–response characteristics to human umbilical vein endothelial cells, human monocyte-like cells (THP-1, ATCC; American Type Culture Collection, Bethesda, MD), and a rat aortic SMC line (RA10, ATCC).

The antiproliferative effect was fully reversible upon withdrawal of mimosine when corrected for cell number (Fig. 4, bottom). After the initial 24-h incubation, DNA synthesis was inhibited by mimosine, but not by kojic acid. Upon drug removal and an additional 24-h recovery period, there was a marked rebound DNA synthesis in the mimosine-arrested, but not in the kojic acid–treated cells. This finding is consistent with synchronous release of a large cohort of SMC from a mimosine-sensitive arrest point just before initiation of DNA replication, an effect previously demonstrated by flow cytometry in other cell types (23). Cell cycle analysis using acridine orange–stained rat SMC confirmed that mimosine induced a reversible accumulation of cells at the G1-S boundary (not shown).

Effect of mimosine and kojic acid on purified human prolyl 4-hydroxylase. The structural similarities between mimosine and 3,4-dihydroxybenzoic acid (Fig. 1), a known prolyl 4-hydroxylase inhibitor, suggested that mimosine and kojic acid might be effective inhibitors. Thus, the interaction of mimosine and kojic acid with the purified human enzyme was investigated. As the active site metal ion is reversibly lost under nontumover conditions, the enzyme becomes metal-depleted during purification and needs to be restored in vitro by the addition of ferrous ions (41). Mimosine interfered with the reconstitution of the active enzyme, showing an apparent IC₅₀ of 120 μM, whereas kojic acid was relatively ineffective, with an apparent IC₅₀ of > 300 μM (Fig. 5). Such a differential effect was also observed for inhibition of deoxyhypusyl hydroxylase in vitro (23), al-
though both compounds share the physicochemical ability to interact with metal ions in solution (42, 43). Thus, only mimosine, but not kojic acid, was inhibitory, apparently by interfering with the apoenzyme to enzyme conversion.

**Effect of mimosine and kojic acid on cellular prolyl 4-hydroxylase activity.** To determine whether these compounds were capable of suppressing prolyl-4-hydroxylase activity in vascular SMC, cells were treated with mimosine for 24 h under proline-free, serum-free conditions before 24-h pulse-labeling with [3H]proline. Mimosine inhibited prolyl hydroxylation activity in human and rat SMC in a dose-dependent manner and at 400–500 μM reduced hydroxyprolyl generation by 80–90%. At that concentration, [3H]proline incorporation, used as a general index for total protein biosynthesis, declined by < 20% in human SMC and was increased by 20% in rat SMC (Fig. 6). These results indicate that mimosine quite specifically inhibits prolyl hydroxylation, with minimal, if any, consequence for the overall synthesis of cellular proteins. In culture, such a preferential effect has been observed before only with agents that directly interact with prolyl 4-hydroxylase, whereas a metal chelator, like 2,2'-dipyridyl, diminishes hydroxyprolyl generation and total protein biosynthesis to the same degree (32). In contrast, kojic acid caused only a 30% reduction in hydroxyproline formation at 500 μM and, thus, was less effective than mimosine. The suppression of cellular prolyl hydroxylation activity by mimosine was rapidly reversible upon removal of the inhibitor. Rat SMC treated with mimosine (500 μM) for 24 h showed hydroxyproline/proline ratios reduced to < 60% of control levels (P < 0.01), which significantly increased to 90% of control levels 24 h after drug withdrawal (P < 0.05).

**Effect of mimosine on the secretion of type I and III procollagens in human vascular SMC.** Type I and III procollagens are the most prominent collagenous proteins synthesized by vascular SMC in their synthetic state, which predominates after passaging in culture and is thought to be representative of cells in vascular lesions (44). Type III procollagen expression increases as a reaction to injury of the rat aorta in vivo (9). In humans, the serum levels of PIINP are known to indicate fibrotic changes in the coronary arteries (45). PIINP is cleaved extracellularly by a specific N-proteinase before fibril formation, and, thus, is a stoichiometric marker for matrix deposition of type III collagen. Consistent with its ability to suppress prolyl hydroxylation, mimosine reduced PIINP secretion to ~ 50% of control levels (Fig. 7). In contrast, the production of PAI-1, a noncollagenous protein, was not affected even at the highest inhibitor concentrations. Thus, it is unlikely that mimosine causes a nonspecific reduction of protein export in general, but, rather, this compound appears to decrease the secretion of proteins which, like the interstitial procollagens, display a triple helical and therefore hydroxyproline-dependent domain. Such a discriminating effect was observed previously with specific prolyl 4-hydroxylase inhibitors like the pyridine dicarboxylates (32).

In vivo, type I collagen is also expressed by SMC in response to vascular injury (9). In the current study, the secretion of procollagen type I was examined by Western blot analysis using a polyclonal antibody directed against the globular, trimeric C-propeptide C3 which is proteolytically cleaved by a specific C-proteinase from the hydroxyproline-containing triple helix in a 1:1 ratio upon secretion (36). The formation in the supernatant of the 72-kD C3 antigen was markedly decreased by mimosine over a 24-h period (Fig. 8). Densitometric analysis of triplicate immunoblots indicated a reduction of C3 to ~ 50% at the highest concentration of mimosine.

The immunological techniques used for measuring C3 and PIINP exhibited less marked decreases in response to mimosine.

**Figure 5.** Inhibition of purified prolyl 4-hydroxylase activity by mimosine. Enzyme activity was determined by trapping of [3H]CO₂ released from a reaction mixture of the human recombinant enzyme, (Pro-Pro-Gly)₉₀ as hydroxylysable substrate, 2-oxo[1-¹⁴C]glutarate, ascorbate, and ferrous sulfate. Data are expressed as a percentage of activity in the absence of inhibitor.

**Figure 6.** Inhibition of prolyl hydroxylation in human coronary and rat aortic SMC by mimosine. SMC derived from a human coronary restenotic lesion (shown in Fig. 2, upper left) or rat aortic SMC were pre-treated with mimosine at the specified levels for 30 min before labeling with [3H]proline for 24 h. The supernatants were TCA precipitated and hydrolyzed, and [3H]proline and [3H]hydroxyproline levels were determined by HPLC. Data are mean±SEM, n = 3 per point.
Figure 7. Secretion of PIIIINP and PAI-1 activity from human coronary SMC. SMC derived from a restenotic coronary plaque were treated under serum-free conditions for 24 h with the specified doses of mimosine followed by PIIIINP RIA (left axis, closed symbols). Data are expressed in milliUnits per milliliter of supernatant (mean±SEM, n = 3). PAI-1 was assayed by fluorometric assay for the inhibition of plasmin generated from urokinase and plasminogen (right axis, open symbols). Levels were interpolated from a standard curve of human PAI-1 expressed in Units per milliliter (mean±SEM, n = 3).

when compared with the nearly complete inhibition of prolyl hydroxylation. The antigenic measures probably underestimate true inhibition for two reasons. First, the antibodies may react with underhydroxylated collagenous peptides that are slowly released from the cells in the presence of inhibitors (25). Sec-

Table I. The Effect of L-Mimosine and Kojic Acid on LDH Release and Trypan Blue Exclusion in Vascular Smooth Muscle Cells

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose</th>
<th>LDH release</th>
<th>SEM</th>
<th>Trypan blue</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mimosine</td>
<td>0</td>
<td>57.00</td>
<td>1.00</td>
<td>0.16</td>
<td>0.011</td>
</tr>
<tr>
<td></td>
<td>500</td>
<td>54.50</td>
<td>0.50</td>
<td>0.40</td>
<td>0.025</td>
</tr>
<tr>
<td>Kojic acid</td>
<td>0</td>
<td>ND</td>
<td></td>
<td>0.16</td>
<td>0.011</td>
</tr>
<tr>
<td></td>
<td>500</td>
<td>ND</td>
<td></td>
<td>0.13</td>
<td>0.019</td>
</tr>
</tbody>
</table>

LDH levels were determined by autoanalyzer in the supernatants of rat aortic SMC incubated with mimosine for 24 h under conditions identical to those used for DNA synthesis studies (n = 2). Hypotonic injury to control cells run in parallel showed a marked elevation of LDH release (114 mU/ml). Trypan blue dye exclusion was performed on rat SMC under similar conditions. The number of positively stained cells, indicating loss of membrane integrity, was expressed as a percentage of cells in each well as determined by a ZBI particle counter (Coulter Corp.) (n = 3).

ond, the antibodies cannot discriminate propeptides formed rapidly during secretion from propeptides slowly released from the matrix.

Toxicity of mimosine and kojic acid. In the time frame tested, no sign of toxicity of mimosine on SMC was observed. In addition to the reversibility of the inhibitory effects on proliferation and collagen hydroxylation, the cells remained viable and biosynthetically active as demonstrated by (a) the number of trypan blue–excluding cells (Table I); (b) the absence of detectable leakage of cytoplasmic LDH (Table I); and (c) the continued synthetic capacities, as reflected by the metabolic labeling of new protein with [3H]proline (Fig. 6) and of precursor eIF-5A with [3H]spermidine (Fig. 3), and by the unaffected secretion of PAI-1 activity (Fig. 7).

Discussion

The vascular response to injury, in the form of cell migration, cell proliferation, and extracellular matrix accumulation, is driven by numerous growth factors and cytokines (1). Because of this inherent mediator redundancy, intentional interruption of the response to an individual mediator may be insufficient to alter the overall tissue reaction. The present strategy targets the pivotal posttranslational hydroxylation of proteins required in the common pathway of both cell proliferation and collagen synthesis, irrespective of which growth factors and cytokines drive these responses. The antifibroproliferative effect of a protein hydroxylase inhibitor, like mimosine, is unconstrained by the biological complexity of the mediator network underlying fibroproliferative diseases.

The intentional interference with specific posttranslational modifications is a widely accepted principle of medical therapeutics and a routine event in clinical practice. The coumarin-like oral anticoagulants are inhibitors of protein carboxylation occurring in Factors II, VII, IX, and X. Likewise, the antithyroid drugs are inhibitors of protein iodination occurring in thyroglobulin. The proposed mechanism for inhibitors of protein hydroxylation, which, like mimosine, affect the production of physiologically structured interstitial procollagens and of eIF-5A, is

Figure 8. Secretion of procollagen type I C-propeptide (C3) by coronary artery SMC. Serum-free supernatants from human coronary restenotic SMC cultures were collected during a 24-h incubation with mimosine. Supernatants were precipitated with 10% TCA, separated by 4–20% SDS-PAGE under nonreducing conditions, transferred to nitrocellulose, and probed with a polyclonal anti-C3 antibody, detected by an immunoperoxidase-labeled anti–mouse antibody from rabbit.

McCaffrey et al.
Prolyl 4-hydroxylase

Deoxyhypusyl hydroxylase

Figure 9. Proposal for the antifibroproliferative effect of a protein hydroxylase inhibitor such as mimosine. The diagram emphasizes the similarity in active site organization between prolyl 4-hydroxylase and deoxyhypusyl hydroxylase with regard to their respective peptide substrate, which in each case displays a -Gly-x-y-Gly motif (glycine residues highlighted in gray), and its relation to the active site metal (Me) which is thought to generate and orient a reactive oxygen atom species (O) for stereospecific attack on the prolyl C4 and the deoxyhypusyl C9 atoms, in this way mediating hydroxylation (arrows) (24, 25, 27). Apparently, mimosine is able to access the tightly bound metal ion (Me) and to block its role in catalysis. Inhibition of prolyl 4-hydroxylase directly suppresses the hydroxyproline-dependent formation and secretion of triple helical collagens (25); inhibition of deoxyhypusyl hydroxylase compromises cell proliferation, by a mechanism not yet completely understood in molecular detail (23).

summarized in Fig. 9. The function suppressed in each biosynthetic pathway is the posttranslational formation of the hydroxylated, peptide-bound amino acid residues trans 4-hydroxyproline and hypusine, which are required for the biological activity of these proteins. In the absence of physiologically structured collagens and eIF-5A, connective tissue formation and cell proliferation both come to a halt independently and both resume rapidly upon removal of the inhibitor. The reversibility of these effects implies that, in vivo, the inhibitor will need to be present until the mitogenic and profibrotic stimuli have subsided.

The present results indicate that a single inhibitor of protein hydroxylation is able to suppress both collagen secretion and cell proliferation in cultured vascular cells of the human coronary arteries and the rat aorta. Mimosine directly inhibits prolyl 4-hydroxylase (Fig. 5) and deoxyhypusyl hydroxylase (23), which in cells blocks the secretion of de novo synthesized collagens (25) and inhibits cell proliferation (23) (Figs. 4 and 6). Inhibition of prolyl 4-hydroxylation leads to intracellular misfolding of only the collagenous proteins, resulting in a dose-dependent reduction of their secretion (32, 46). Apparently, mimosine selectively inhibits hydroxylase activity, which resides in the α subunits of prolyl 4-hydroxylase (47), but does not compromise the role of its β subunits in the intracellular retention of misfolded procollagens (48).

The simultaneous suppression of both protein hydroxylases by a single agent implies that, in addition to the similarities in their peptide binding sites, the active sites of prolyl 4-hydroxylase and deoxyhypusyl hydroxylase are structured alike. Indeed, the three-dimensional models proposed for the architecture of each enzyme’s active site (24, 25, 27) show common structural elements which outline the structure–activity relation for the dual action of mimosine.

In both enzymes, the protein-bound metal atom at the active site, proposed to mediate the hydroxylation by transfer of an oxygen atom (Fig. 9), provides coordination sites for a bidentate ligand. The active sites are thought to also display a polar amino acid side chain able to form a stabilizing salt bridge with an appropriately charged ligand, requiring a negative charge in case of prolyl 4-hydroxylase and a positive charge in case of deoxyhypusyl hydroxylase (24, 25, 27). We propose that these structural prerequisites for interaction with either enzyme are met by the amino acid moiety of mimosine. Its ionic interaction
positions the 3-hydroxy-4-keto moiety to chelate the active site metal of each protein hydroxylase. This hypothesis accounts for the fact that mimosine-like molecules require a carboxyl moiety to inhibit procollagen formation (29, 49), whereas they require an amino group to inhibit proliferation (50). These distinctions may be useful for the further development of compounds that selectively target only one protein hydroxylase. Indeed, the potent prolyl 4-hydroxylase antagonist pyridine 2,4-dicarboxylate and pyridine 2,5-dicarboxylate (28) lack the ability to inhibit deoxypseudohydroxylase (20) and they do not affect cell proliferation or cell cycle transit (McCaffrey, T. A., and H. M. Hanauske-Abel, unpublished observation).

The prerequisite for interaction with both the charged side chains and the metal ion appears to be quite stringent for prolyl 4-hydroxylase and for deoxypseudohydroxylase, as evidenced by the findings obtained with kojic acid. This agent, which cannot bind to the charged side chain at the active site of either enzyme, but whose ring is bioisosteric to the one in mimosine (Fig. 1) and like mimosine interacts with metal, was not inhibitory for deoxypseudohydroxylase (23) and only weakly inhibitory for prolyl 4-hydroxylase (Fig. 5). Therefore, the ability to bind metal is, by itself, not sufficient to effectively access the active site of either prolyl 4-hydroxylase or deoxypseudohydroxylase and inhibit enzyme activity. Generalized metal chelation by an agent like desferrioxamine can, however, reduce vascular SMC proliferation in vitro and in vivo (51).

After oral administration in animals, plasma levels of mimosine could be maintained in the range of concentrations that were biologically active in the present studies (100-300 μM) (52). However, because both protein hydroxylases have important functions in normal tissue, ideally their use would be restricted to the site of the fibroproliferative response. Fortunately, drugs, or bioactivatable produgs, could be applied locally either by a perfusion catheter (53) or by resorbable vascular stents acting as a depot for the slow release of agent into the local environment (54). Intramuscular application of these agents would also place the inhibitor beneath the intimal surface and would thus minimize the antiproliferative effect on reendothelialization, which occurs both by migration and proliferation (55). Thus, the antifibrolproliferative action of protein hydroxy-
lase inhibitors could be targeted to specific vascular regions to interfere with the establishment of an intralesional collagenous nidus of factors that sustain the fibroproliferative response. Protein hydroxylase inhibitors, like mimosine, will be useful tools for determining the impact of cell proliferation and collagen synthesis in vascular restenosis and other fibroproliferative disorders.

Acknowledgments

The authors wish to thank Hoechst AG for providing technical support and access to the radioimmunoassays for determination of human pro-
collagen type III NH₂-terminal propeptide. The authors are indebted to Dr. Ken Emcapator for generous use of the Synchro C7X autoana-
lizer. H. M. Hanauske-Abel wishes to thank Dr. Maria New for special assistance. H. M. Hanauske-Abel was supported in part by the Evariste Galois Fund and the Council for Tobacco Research. The contributions of K. I. Kivirikko and A. Lamber were made possible by grants from the Medical Research Council of the Academy of Finland. T. A. McCaffrey is a recipient of an NIH FIRST Award (HL-42606). T. A. McCaffrey, K. Pomerantz, and D. Falcone are members of an NIH Program Project in Atherosclerosis (HL-46403). Parts of this work were conducted in association with an NIH SCOR in Thrombosis (HL-18828).

References

17. Bashkin, P., S. Docrow, M. Klagsvns, C. M. Shavan, J. Folkman, and I. Vlodavsky. 1989. Basic fibroblast growth factor binds to subendothelial extracel-
lular matrix and is released by heparinase and heparin-like molecules. Biochemistry. 28:1737–1743.
for the catalytic mechanism of prolylhydroxylase. Applicability to classification and design of inhibitors. 


44. Mayne, R. 1987. Vascular connective tissue: normal biology and derange-


273.

47. Kivirikko, K. I., R. Myllyla, and T. Pihlajaniemi. 1989. Protein hydroxyla-

ciation with protein disulfide isomerase/prolyl hydroxylase of type I procolla-


tery Dis. 4:469–475.

54. Rogers, C., M. J. Karnovsky, and E. R. Edelman. 1993. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascu-